Lu Lu

TL;DR: It is reported for the first time that a SARS-CoV-specific human monoclonal antibody,CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM), suggesting that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019- nCoV infections.

TL;DR: EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.

TL;DR: The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus.

TL;DR: A novel coronavirus, 2019-nCoV, emerged in Wuhan, China and then quickly spread worldwide, resulting in >17,388 confirmed cases and 361 deaths as of 3 February 2020, thus calling for the development of safe and effective therapeutics and prophylatics.

TL;DR: Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-H CoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.